SCHEMBL7189515

SCHEMBL7189515

COc1ccc(PC(=O)c2c(C)cccc2C)cc1.[LiH]

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ALDH1A1 P00352 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
TSHR P16473 1/20 0.42
MAPK1 P28482 1/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 1/20 0.41
THRB P10828 1/20 0.40
FFAR4 Q5NUL3 1/20 0.40
CES2 O00748 2/20 0.39
CES1 P23141 2/20 0.39
LMNA P02545 1/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
HPGD P15428 1/20 0.38
KDM4E B2RXH2 1/20 0.38
F3 P13726 1/20 0.38
CCR5 P51681 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7182030 0.90 KMT2A (0.41) ATMTDP1L3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL7177349 0.86 ALDH1A1 (0.43) TDP1L3MBTL1ALDH1A1FFAR4CES2
SCHEMBL7180835 0.84 MEN1 (0.43) L3MBTL1ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL7175420 0.84 CA12 (0.49) ATMTDP1L3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL7182801 0.84 KMT2A (0.46) ALDH1A1SMN1; SMN2NPC1RAB9ACES2
SCHEMBL7188651 0.84 PPARG (0.33) ATMTDP1L3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL7188875 0.83 PARP10 (0.41) TDP1ALDH1A1SMN1; SMN2TSHRNPC1
SCHEMBL7188453 0.83 POLB (0.43) ALDH1A1NPC1RAB9ALMNAKDM4E
SCHEMBL7175205 0.83 ACACB (0.33) L3MBTL1TSHRKDM4ECCR5MEN1
SCHEMBL7179880 0.83 L3MBTL1 (0.35) TDP1L3MBTL1ALDH1A1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 ATM 2823/4885TDP1 4234/4885L3MBTL1 302/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 ATM 2935/4885TDP1 4275/4885L3MBTL1 126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.